ReCor Medical, Inc.
12
6
9
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
50%
1 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Global Paradise System US Post Approval Study
Role: lead
A Study of the ReCor Medical Paradise System in Clinical Hypertension
Role: lead
The RADIANCE CED Study
Role: lead
Safety and Efficacy of Ultrasound Renal Denervation in Kidney Transplantation Patients With Uncontrolled Hypertension
Role: collaborator
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension
Role: lead
Renal Denervation to Treat Heart Failure With Preserved Ejection Fraction
Role: collaborator
RADIANCE Continued Access Protocol
Role: lead
The "Global Paradise System" Registry
Role: lead
REducing Sympathetic Activity Through Ultrasound-based Renal deneRvation in Excessive Cardiovascular Risk populaTions.
Role: collaborator
Effect of Renal Denervation on Stress, Hypertension and Anxiety Management
Role: collaborator
TrAnsCatHeter Intravascular Ultrasound Energy deliVery for rEnal Denervation (ACHIEVE)
Role: lead
REnAL denervatIon by ultraSound Transcatheter Emission
Role: lead
All 12 trials loaded